Global
Anti-viral drugs Market Information, by application (hepatitis, HIV/AIDS,
herpes, influenza and others) and by mechanism of action (nucleotide polymerase
inhibitors, reverse transcriptase inhibitors, protease inhibitors and others) -
Forecast to 2022
Market Scenario:
The rising cases of viral disease is identified to
boost the global anti-viral drugs market growth. The inadequacy of dietary
nutrition in people, due to increase in consumption of high calorie and low
fibrous food is creating favourable condition for virus to invade human body.
Hence, the need for anti-viral drugs are surging as viral infections prevail.
The growing incidences of HIV and other sexually-transmitted diseases are also
boosting the sales number of anti-viral drugs, hence, anticipated to prompt the
anti-viral drug market growth.
The increase in cases of drug resistance is
propelling extensive research and developmental undertakings for launching more
effective anti-viral drugs. Additionally, the stringency in drug approval
stages are taking care of the quality of drugs in the pipeline. New product
launches are gaining traction for revenue generation for the anti-viral
drugs market. The application of anti-viral drugs in other diseases
like, bird flu, and others is also likely to prompt the global anti-viral drug
growth.
The expiry of patents for certain blockbuster
anti-viral drug are stimulating generic drug competition in the anti-viral drug
market. This is deepening the competitive scenario of the global anti-viral
drug market over the assessment period.
However, adverse effects of anti-viral drugs and
high price of anti-viral drugs can hinder the anti-viral drugs market growth
over the assessment period.
Market Segmentation:
Global anti-viral drugs market has been
segmented on the basis of on the basis of application, which comprises
hepatitis, HIV/AIDS, herpes, influenza and others. On the basis of mechanism of
action; market is segmented into nucleotide polymerase inhibitors, reverse
transcriptase inhibitors, protease inhibitors and others.
Regional Analysis:
Depending on geographic region,
anti-viral drugs market is segmented into four key regions: America, Europe,
Asia Pacific, and Middle East & Africa. Globally, America is the largest
market for anti-viral drugs with Europe tied for the second space. Asia Pacific
region is expected to be fastest growing region in anti-viral drugs
market.
Key Players
MRFR have enlisted some of the prominent
companies operating in the anti-viral drugs market. They are; Hoffmann-La Roche
Ltd., Johnson & Johnson, Merck & Co. Inc., Gilead Sciences Inc., Cipla
Inc. GlaxoSmithKline Plc, Novartis International AG, Abbott Laboratories,
and Astra Zeneca AB.
Browse more Pharmaceutical Reports @ https://www.marketresearchfuture.com/categories/pharmaceutical-market-report